Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Joel Bass"'
Development of combination strategies for focal adhesion kinase inhibition in diffuse gastric cancer
Autor:
Ke Peng, Adam Joel Bass
Publikováno v:
Journal of Clinical Oncology. 40:e16057-e16057
e16057 Background: Diffuse gastric cancer (DGC) is an aggressive and frequently lethal pathological subtype of gastric cancer (GC). Since DGC often lacks genomic aberrations that indicate clear candidate therapeutic targets, it has been challenging t
Autor:
Rachael A Safyan, Gulam Abbas Manji, Shing Mirn Lee, Rebecca Silva, Susan Elaine Bates, Ruth Aroon White, Jacob K.R. Jamison, Adam Joel Bass, Gary K. Schwartz, Paul Eliezer Oberstein, Tamas Gonda
Publikováno v:
Journal of Clinical Oncology. 40:4158-4158
4158 Background: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death with a 5-year survival rate of 10%. Novel strategies for advanced PDAC are a critical need. A DNA hypomethylating agent (HMA) increased tumor-
Autor:
James Bailen, Michael L. Hancock, Joel Bass, Michael Gambla, Robert Given, Franklin Chu, Franklin Gaylis, Marc M. Gittelman, Mitchell S. Steiner, Christopher C. Coss, Laurence Belkoff, Evan Y. Yu, Robert H. Getzenberg, Ronald F. Tutrone, Thomas E. Keane, Jordan Smith, James T. Dalton
Publikováno v:
European Urology. 67:334-341
Background A need remains for new therapeutic approaches for men with advanced prostate cancer, particularly earlier in the disease course. Objective To assess the ability of an oral selective estrogen receptor α agonist (GTx-758) to lower testoster
Autor:
Thomas E. Keane, James T. Dalton, Joel Bass, Mike Gambla, Ronald Tutrone, Marc Gittelman, Evan Y. Yu, Robert H. Getzenberg, Robert Given, Michael L. Hancock, Franklin Gaylis, Laurence Belkoff, James Bailen, Mitchell S. Steiner, Christopher C. Coss, Franklin Chu
Publikováno v:
Journal of Clinical Oncology. 31:171-171
171 Background: The insulin pathway and, in particular, insulin-like growth factor-1 (IGF-1), has been implicated in the development of prostate cancer, and serum IGF-1 levels have been associated with advanced disease. GTx-758, an ERα agonist that
Autor:
Thomas E. Keane, Franklin Gaylis, Michael L. Hancock, James Bailen, Joel Bass, Ronald Tutrone, Evan Y. Yu, Robert H. Getzenberg, Christopher C. Coss, Mike Gambla, Franklin Chu, Mitchell S. Steiner, Laurence Belkoff, James T. Dalton
Publikováno v:
Journal of Clinical Oncology. 31:222-222
222 Background: Men with advanced prostate cancer are being treated with androgen deprivation therapy (ADT) for longer periods of time. The use of ADT can be limited by estrogen deficiency side effects, including a loss of bone and a higher incidence
Autor:
Mike Gambla, Robert Given, Joel Bass, Michael L. Hancock, Laurence Belkoff, Marc Gittelman, James T. Dalton, Franklin Gaylis, Thomas E. Keane, Evan Y. Yu, Robert H. Getzenberg, Mitchell S. Steiner, Ronald Tutrone, James Bailen, Christopher C. Coss, Franklin Chu
Publikováno v:
Journal of Clinical Oncology. 31:104-104
104 Background: Androgen deprivation therapy (ADT) improves disease-free survival in men with advanced prostate cancer, but patients develop castrate resistant prostate cancer (CRPC); one of the causes of which is ineffective castration. Total serum
Autor:
Michael L. Hancock, James Bailen, Joel Bass, Evan Y. Yu, Robert H. Getzenberg, Christopher C. Coss, Mike Gambla, Thomas E. Keane, Franklin Chu, Mitchell S. Steiner, Laurence Belkoff, Marc Gittelman, James T. Dalton, Franklin Gaylis, Ronald Tutrone
Publikováno v:
Journal of Clinical Oncology. 31:129-129
129 Background: When androgen deprivation therapy (ADT) for prostate cancer was first developed, life expectancy for men with advanced disease was short and the systemic effects were of limited relevance. GTx-758 is a selective ERα agonist that effe
Autor:
M D Joel Bass
Publikováno v:
Hepatology. 18:224-225
Autor:
Joel Bass, Dorothea Johnson, Jacqueline Kirby, George A. Lamb, Janice C. Levy, Paul L. McCarthy, Carol Robins, Cynthia Ross
Publikováno v:
Pediatrics. 54:251-251
We read with interest Dr. Nathan's comments on primary medical care (Pediatrics, 52:768, 1973), but feel compelled to add another viewpoint. One of the striking changes occurring today in teaching hospitals and medical schools is an increased awarene